CA2434046A1 - Ajustement de dosage pour antibiotiques - Google Patents

Ajustement de dosage pour antibiotiques Download PDF

Info

Publication number
CA2434046A1
CA2434046A1 CA002434046A CA2434046A CA2434046A1 CA 2434046 A1 CA2434046 A1 CA 2434046A1 CA 002434046 A CA002434046 A CA 002434046A CA 2434046 A CA2434046 A CA 2434046A CA 2434046 A1 CA2434046 A1 CA 2434046A1
Authority
CA
Canada
Prior art keywords
patients
antibiotic
infection
synercid
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002434046A
Other languages
English (en)
Inventor
Issam Raad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2434046A1 publication Critical patent/CA2434046A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a trait à un ajustement de dosage et à un ajustement de la fréquence d'administration des antibiotiques qui sont excrétés, en majeur partie, par les voies biliaires à partir des examens des fonctions hépatiques, dans le but de diminuer les effets secondaires provoqués par l'antibiotique.
CA002434046A 2001-01-11 2002-01-11 Ajustement de dosage pour antibiotiques Abandoned CA2434046A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26143701P 2001-01-11 2001-01-11
US60/261,437 2001-01-11
PCT/US2002/000775 WO2002055731A2 (fr) 2001-01-11 2002-01-11 Ajustement de dosage pour antibiotiques

Publications (1)

Publication Number Publication Date
CA2434046A1 true CA2434046A1 (fr) 2002-07-18

Family

ID=22993291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002434046A Abandoned CA2434046A1 (fr) 2001-01-11 2002-01-11 Ajustement de dosage pour antibiotiques

Country Status (4)

Country Link
EP (1) EP1360316A2 (fr)
AU (1) AU2002241849A1 (fr)
CA (1) CA2434046A1 (fr)
WO (1) WO2002055731A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4972081B2 (ja) 2005-03-14 2012-07-11 ワイス・エルエルシー チゲサイクリン組成物および調製方法

Also Published As

Publication number Publication date
AU2002241849A1 (en) 2002-07-24
WO2002055731A3 (fr) 2003-08-14
EP1360316A2 (fr) 2003-11-12
WO2002055731A2 (fr) 2002-07-18

Similar Documents

Publication Publication Date Title
Enoch et al. Daptomycin
Gould Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus
Eisenstein Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections
Tedesco et al. Daptomycin
US5883074A (en) Potentiators of antibacterial agents
Kauffman Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections
Karlsson et al. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis
Delgado Jr et al. Quinupristin‐dalfopristin: an overview
Lauritzen et al. Putative biomarkers for evaluating antibiotic treatment: an experimental model of porcine Actinobacillus pleuropneumoniae infection
Brandt et al. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents
Fitzgibbons et al. Management of gram-positive coccal bacteremia and hemodialysis
Zhanel et al. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa
Risinger et al. Targeting and extending the eukaryotic druggable genome with natural products: Cytoskeletal targets of natural products
Allen et al. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model
CA2459822C (fr) Traitement de la leucemie myeloide chronique, resistante ou intolerante au sti571, impliquant l'homoharringtonine seul ou en combinaison avec d'autres agents
Basu et al. Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine
Lampejo Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review
Goldstein et al. Teicoplanin
US20120252896A1 (en) Methods and compositions for modulation of t-cells via the kynurenine pathway
Onyeji et al. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia
Qian et al. Dual roles of p62/SQSTM1 in the injury and recovery phases of acetaminophen-induced liver injury in mice
Kobayashi et al. Therapeutic efficacy of once‐daily oral administration of a Kunitz‐type protease inhibitor, bikunin, in a mouse model and in human cancer
CA2434046A1 (fr) Ajustement de dosage pour antibiotiques
Maxwell-Scott et al. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents
Moore et al. Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin

Legal Events

Date Code Title Description
FZDE Discontinued